1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 20,400 | 22,000 | 13.01. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | Goldman Sachs stuft Sartorius Stedim Biotech nach Kursrallye herab | 3 | Investing.com Deutsch | ||
| SARTORIUS STEDIM BIOTECH SA ADR Aktie jetzt für 0€ handeln | |||||
| Mo | Goldman Sachs downgrades Sartorius Stedim Biotech stock rating after recent rally | 3 | Investing.com | ||
| 06.01. | Sartorius Stedim Biotech SA: Half-year liquidity contract statement for Sartorius Stedim Biotech | 389 | Dow Jones News | DJ Sartorius Stedim Biotech SA: Half-year liquidity contract statement for Sartorius Stedim Biotech
Sartorius Stedim Biotech SA
Sartorius Stedim Biotech SA: Half-year liquidity contract statement... ► Artikel lesen | |
| 05.01. | Sartorius Stedim Biotech SA: Declaration Relative to the Number of Shares and Voting Rights Making up the Issued Capital | 333 | Dow Jones News | DJ Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA
Sartorius Stedim Biotech SA: DECLARATION... ► Artikel lesen | |
| 03.12.25 | Sartorius Stedim Biotech SA: Declaration Relative to the Number of Shares and Voting Rights Making up the Issued Capital | 443 | Dow Jones News | DJ Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA
Sartorius Stedim Biotech SA: DECLARATION... ► Artikel lesen | |
| 03.11.25 | Sartorius Stedim Biotech SA: Declaration Relative to the Number of Shares and Voting Rights Making up the Issued Capital | 475 | Dow Jones News | DJ Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA
Sartorius Stedim Biotech SA: DECLARATION... ► Artikel lesen | |
| 16.10.25 | Earnings Call: Sartorius Stedim Biotech steigert Umsatz in Q3 2025 um 7,5 % | 3 | Investing.com Deutsch | ||
| 16.10.25 | Sartorius Stedim Biotech Non-GAAP EPS of €0.94, revenue of €705.7M; raises FY outlook | 3 | Seeking Alpha | ||
| 16.10.25 | Sartorius Stedim Biotech Earnings Up In H1; Lifts FY25 Outlook | 409 | AFX News | PARIS (dpa-AFX) - Sartorius Stedim Biotech S.A. (DIM.PA), a partner to the biopharmaceutical industry, on Thursday reported that net profit increased in the first half of 2025 compared with... ► Artikel lesen | |
| 16.10.25 | Sartorius Stedim Biotech SA: Sartorius Stedim Biotech publishes unaudited results for the first nine months of 2025 | 538 | EQS Group (EN) | Sartorius Stedim Biotech SA
/ Key word(s): 9 Month figures
Sartorius Stedim Biotech publishes unaudited results for the first nine months of 2025 16-Oct-2025 / 07:00 CET/CEST
Aubagne... ► Artikel lesen | |
| 06.10.25 | Sartorius Stedim Biotech SA: Declaration Relative to the Number of Shares and Voting Rights Making up the Issued Capital | 498 | Dow Jones News | DJ Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA
Sartorius Stedim Biotech SA: DECLARATION... ► Artikel lesen | |
| 02.09.25 | Sartorius Stedim Biotech SA: Declaration Relative to the Number of Shares and Voting Rights Making up the Issued Capital | 617 | Dow Jones News | DJ Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA
Sartorius Stedim Biotech SA: DECLARATION... ► Artikel lesen | |
| 12.08.25 | Sartorius Stedim Biotech beteiligt sich an Nanotein Technologies | 8 | transkript.de | ||
| 11.08.25 | Sartorius Stedim Biotech & Nanotein Technologies to Advance Cell Therapy Manufacturing | 2 | Contract Pharma | ||
| 04.08.25 | Sartorius Stedim Biotech SA: Declaration Relative to the Number of Shares and Voting Rights Making up the Issued Capital | 681 | Dow Jones News | DJ Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA
Sartorius Stedim Biotech SA: DECLARATION... ► Artikel lesen | |
| 23.07.25 | Sartorius Stedim Biotech stock rating upgraded by RBC Capital to Outperform | 4 | Investing.com | ||
| 23.07.25 | RBC Kapital stuft Sartorius Stedim Biotech auf 'Outperform' hoch | 3 | Investing.com Deutsch | ||
| 22.07.25 | Sartorius Stedim Biotech reports 9.4% sales growth in first half | 10 | Investing.com | ||
| 22.07.25 | Sartorius Stedim Biotech H1 Net Profit Rises; Confirms Guidance For 2025 | 676 | AFX News | BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - Sartorius Stedim Biotech reported that its first half net profit increased to 154.1 million euros from 104.0 million euros, last year. Earnings per share... ► Artikel lesen | |
| 22.07.25 | Sartorius Stedim Biotech SA: Information on Document Availability | 860 | Dow Jones News | DJ Sartorius Stedim Biotech SA: Information on Document Availability
Sartorius Stedim Biotech SA
Sartorius Stedim Biotech SA: Information on Document Availability
22-Jul-2025 / 07:02 CET/CEST... ► Artikel lesen |
1 2 Weiter >>
37 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PRAXIS PRECISION MEDICINES | 280,83 | +1,80 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Further Positioned for Next-Phase Growth with Key Board and Executive Appointments | BOSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies... ► Artikel lesen | |
| STRUCTURE THERAPEUTICS | 77,92 | +12,34 % | Cantor Fitzgerald reiterates Structure Therapeutics stock rating at Overweight | ||
| IMMUNOME | 20,140 | -2,09 % | Immunome: Guggenheim bestätigt Kaufempfehlung nach 400-Millionen-Dollar-Finanzierung | ||
| BEAM THERAPEUTICS | 34,550 | +2,55 % | AKTIONÄR-Tipp Beam Therapeutics wie entfesselt: Die Hintergründe! | Innerhalb der Biotech-Branche zählt der Bereich Gen-Schere zu den absoluten Top-Trends. Neben der wohlbekanntesten seiner Klasse, CRISPR/Cas9, entwickeln sich auch andere Ansätze weiter. Dazu zählt... ► Artikel lesen | |
| BIONTECH | 92,05 | +5,20 % | mRNA Patentstreit: Bayer zieht BioNTech, Pfizer und Moderna vor Gericht | © Foto: Juan Vega - EUROPA PRESSBayer erhebt schwere Patentvorwürfe gegen die Hersteller der erfolgreichsten Corona-Impfstoffe. Im Zentrum steht eine mRNA-Technologie aus den 1980er-Jahren.Der Agrar-... ► Artikel lesen | |
| QIAGEN | 40,415 | -1,26 % | PTA-NVR: QIAGEN N.V.: Veröffentlichung der Gesamtzahl der Stimmrechte nach § 41 WpHG | DJ PTA-NVR: QIAGEN N.V.: Veröffentlichung der Gesamtzahl der Stimmrechte nach § 41 WpHG
Gesamtstimmrechte gemäß -- 41 WpHG
QIAGEN N.V.: Veröffentlichung der Gesamtzahl der Stimmrechte nach... ► Artikel lesen | |
| VERA THERAPEUTICS | 49,100 | +5,68 % | Vera Therapeutics Announces U.S. FDA Granted Priority Review to Biologics License Application for Atacicept for Treatment of Adults with IgA Nephropathy | FDA assigned PDUFA target action date of July 7, 2026.If approved, atacicept would be the first B cell modulator targeting both BAFF and APRIL for IgAN.Atacicept received FDA Breakthrough Therapy... ► Artikel lesen | |
| ADMA BIOLOGICS | 17,700 | -1,31 % | ADMA Biologics reports FY 2025 revenue in line with estimate, provides 2026-2029 outlook | ||
| ALUMIS | 22,110 | +4,84 % | Alumis Inc.: Alumis Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares | SOUTH SAN FRANCISCO, Calif., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing next-generation targeted therapies for patients with... ► Artikel lesen | |
| COGENT BIOSCIENCES | 35,280 | +1,53 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Anticipated 2026 Commercial and Clinical Milestones for Bezuclastinib and Precision Therapies Portfolio | New Drug Application (NDA) for NonAdvSM submitted in December 2025, NDA submission for AdvSM on track for 1H 2026NDA submission for GIST on track for April 2026; bezuclastinib has the potential to... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 74,13 | +1,35 % | Kymera Therapeutics, Inc.: Kymera Therapeutics Outlines Key 2026 Objectives and Strategy to Advance Industry Leading Portfolio of Oral Immunology Programs | KT-621 BROADEN2 Phase 2b trial in AD ongoing, with data expected by mid-2027 KT-621 BREADTH Phase 2b trial in asthma initiated, with data expected in late-2027 KT-579 Phase 1 HV clinical trial expected... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 32,940 | -0,12 % | Mineralys Therapeutics, Inc. - 8-K, Current Report | ||
| HARMONY BIOSCIENCES | 35,760 | -6,58 % | Harmony Biosciences: WAKIX-Umsatz soll 2026 die Marke von 1 Milliarde US-Dollar übersteigen | ||
| DYNE THERAPEUTICS | 17,040 | -2,38 % | Dyne Therapeutics, Inc. - 8-K, Current Report | ||
| ARCELLX | 66,75 | +2,90 % | UBS initiates Arcellx stock coverage with Buy rating, $100 price target |
Das Unternehmen SARTORIUS STEDIM BIOTECH SA ADR kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -4,67 % bei einem Aktienkurs von 20,400 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SARTORIUS STEDIM BIOTECH SA ADR finden Sie auf Wallstreet Online.